Go to main page


Rapid Development and Scale-up of Solubilized Dosage Forms

March 22, 2018

Register to view on-demand recording

On-Demand Recording: Rapid Scale-up and Development of Solubilized Dosage Forms
    You may unsubscribe from these communications at any time. Every email we send you will also include an unsubscribe link so you can unsubscribe from our marketing list. For more information on our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Enhancement of Poorly Soluble Drugs

About 40% of approved and 90% of pipeline drugs are poorly soluble, their maximum absorbable dose limited by aqueous solubility. This has led to the adoption of enabled and solubilized dosage forms to deliver these drugs more effectively, including amorphous solid dispersions. Amorphous dispersions are a broadly applicable approach that have been shown to improve API solubility, dissolution rates, and bioavailability of poorly soluble drugs.

This presentation covers:

  • Advantages of amorphous drugs
  • Development of amorphous solid dispersions using spray drying and hot melt extrusion
  • Scale-up of solubilized dosage forms



Ruchit Trivedi, PhD

Associate Director of Formulation, BioDuro